Here's Why Conestoga Capital Advisors Sold Mesa Laboratories (MLAB)
Conestoga Capital Advisors sold its position in Mesa Laboratories (MLAB), citing a lack of conviction in the company’s long-term growth prospects. The asset management firm noted that MLAB's operating results were pressured by end-market weakness, particularly in cell and gene therapy and China, and that its acquisition strategy had not delivered anticipated growth. Conestoga concluded that limited organic growth opportunities and a constrained balance sheet limit MLAB’s overall growth potential.
As worker safety scrutiny intensifies, Mesa Labs reinforces why primary standard calibration is the only line of defense
Mesa Labs is recommitting to advancing its DryCal primary standard calibration technology due to increased regulatory scrutiny and a generational shift in the workforce affecting workplace exposure monitoring. Inaccurate air sampling pump calibration, often relying on less precise secondary standards, poses a significant risk to worker safety. Mesa Labs aims to educate professionals on the importance of primary standards, noted by OSHA's adoption of their Defender series calibrators.
As Worker Safety Scrutiny Intensifies, Mesa Labs Reinforces Why Primary Standard Calibration Is the Only Line of Defense
Mesa Laboratories is emphasizing the critical role of primary standard calibration, specifically its DryCal product line, in ensuring worker safety amidst increasing regulatory scrutiny and a generational knowledge gap in industrial hygiene. The company highlights that unlike secondary standards, their primary standards provide direct, accurate measurements crucial for detecting hazardous exposures, a distinction recognized by OSHA which has standardized its field enforcement on Mesa's Defender series calibrators. Mesa Labs is also partnering with AIHA to educate professionals on flow calibration essentials and the importance of precise instrumentation.
As Worker Safety Scrutiny Intensifies, Mesa Labs Reinforces Why Primary Standard Calibration Is the Only Line of Defense
Mesa Laboratories is emphasizing the critical role of primary standard calibration, particularly through its DryCal product line, amidst increasing regulatory scrutiny on worker safety and a generational knowledge gap in flow calibration. OSHA has standardized its field enforcement operations on Mesa’s Defender series calibrators, highlighting the need for accurate air sampling in hazardous environments. Mesa Labs is also partnering with the AIHA to provide education on calibration essentials for occupational health and safety professionals.
Mesa Laboratories, Inc. $MLAB Shares Acquired by Herald Investment Management Ltd
Herald Investment Management Ltd significantly increased its stake in Mesa Laboratories (MLAB) by 300%, now owning 50,000 shares worth $3.34 million. This move is part of broader institutional investment, with various hedge funds also adjusting their positions in the medical instruments supplier. Despite Mesa Laboratories reporting an earnings beat, analysts maintain a "Reduce" consensus rating with a target price of $94.00, while the company also announced a quarterly dividend of $0.16 per share.
Mesa Laboratories, Inc. $MLAB Shares Bought by Diamond Hill Capital Management Inc.
Diamond Hill Capital Management Inc. significantly increased its stake in Mesa Laboratories (MLAB) by 218% in Q3, now owning 2.24% of the company worth $8.27 million. Institutional investors collectively hold approximately 90.6% of the stock. Analyst ratings are mixed, with a MarketBeat consensus of "Reduce" and a target price of $94, while the company recently exceeded Q3 earnings and revenue expectations and declared a quarterly dividend.
Mesa Laboratories (NASDAQ:MLAB) Upgraded by Wall Street Zen to Strong-Buy Rating
Wall Street Zen upgraded Mesa Laboratories (NASDAQ:MLAB) from a "buy" to a "strong-buy" rating, causing the stock to trade up 2.3% to $93.27. The company recently beat quarterly earnings estimates with an EPS of $3.07 on $65.13 million in revenue, though it carries a high P/E ratio of 145.74. While analyst views are mixed with an average target price of $94, institutional ownership remains high at 90.6%.
Mesa Laboratories (MLAB) Quarterly Profit Return Tests Longstanding Bearish Loss Narratives
Mesa Laboratories (MLAB) recently reported a quarterly profit of US$0.45 EPS on US$60.7 million revenue, contrasting with a US$1.6 million net loss over the trailing twelve months. Despite historical losses, analysts forecast 3.7% annual revenue growth and 16.3% earnings growth, leading to a mixed outlook on profitability. The stock currently trades at a 2x P/S multiple, below its peers and a DCF fair value of US$147.77, suggesting potential undervaluation if the company sustains its recent return to quarterly profits.
Mesa Labs Announces Third Quarter Results
Mesa Laboratories, Inc. (NASDAQ:MLAB) has announced its financial results for the third fiscal quarter ended December 31, 2025 (3Q26). The company reported a 3.6% increase in revenues and a 38.0% increase in operating income. Non-GAAP adjusted operating income, excluding unusual items, rose by 15.4% to 26.2% as a percentage of revenues, and Mesa also repaid $8.7 million of debt, reducing its Total Net Leverage Ratio to 2.62.
MESA LABORATORIES INC /CO/ SEC 10-Q Report
Mesa Laboratories Inc. (MLAB) has released its 10-Q report for the period ending December 31, 2025, showing significant financial and operational improvements. The company reported increased revenues and a swing from a net loss to a net income, driven by growth in its Biopharmaceutical Development and Sterilization and Disinfection Control divisions. Despite challenges in the Clinical Genomics division in China, Mesa Labs anticipates continued profitability through strategic initiatives and cost reduction.
Mesa Labs: Fiscal Third Quarter Earnings Overview
Mesa Laboratories Inc. reported its fiscal third-quarter results, achieving a profit of $3.6 million, or $0.65 per share. When adjusted for one-time expenses and amortization, the company's earnings rose to $3.07 per share. During this quarter, the manufacturer of quality control instruments and disposable products generated $65.1 million in revenue.
Mesa Labs Announces Third Quarter Results
Mesa Laboratories, Inc. (MLAB) has announced its financial results for the third fiscal quarter ended December 31, 2025, reporting a 3.6% year-over-year revenue increase to $65.1 million and a substantial 317.0% surge in net income to $3.6 million. The company showcased strong performance in its Sterilization and Disinfection Control (SDC) and Biopharmaceutical Development (BPD) divisions, with management expressing optimism for continued positive momentum in the upcoming quarter.
Mesa Labs Announces Third Quarter Results
Mesa Laboratories, Inc. (NASDAQ:MLAB) announced its third-quarter fiscal year 2026 results, reporting a 3.6% increase in revenues and a 38.0% increase in operating income. The company achieved 3.6% organic revenues growth, or 5.7% excluding CG China revenues, and reduced its Total Net Leverage Ratio to 2.62. Mesa's CEO highlighted steady execution, strong growth in Biopharmaceutical Development, and a recovery in Sterilization and Disinfection Control, with expectations for continued positive momentum.
Mesa Laboratories Earnings Report: Q3 Overview
Mesa Laboratories (NASDAQ: MLAB) announced its Q3 earnings, reporting an EPS of $3.07, significantly beating the estimated $1.6 by 92.0%. Revenue also increased by $2.29 million compared to the same period last year. This strong performance follows a previous quarter where the company also surpassed EPS estimates, leading to a 2.0% increase in share price the following day.
Mesa Labs: Fiscal Q3 Earnings Snapshot
Mesa Laboratories Inc. (MLAB) reported earnings of $3.6 million in its fiscal third quarter, translating to 65 cents per share. Adjusted earnings were $3.07 per share, while the company posted revenue of $65.1 million for the period.
Mesa Labs: Fiscal Third Quarter Earnings Overview
Mesa Laboratories Inc. has reported its financial results for the fiscal third quarter, achieving a profit of $3.6 million and earnings of $0.65 per share. Adjusted earnings, excluding one-time expenses and amortization, reached $3.07 per share. The company, which specializes in quality control instruments, generated $65.1 million in revenue during this period.
Short Interest in Mesa Laboratories, Inc. (NASDAQ:MLAB) Decreases By 12.1%
Short interest in Mesa Laboratories, Inc. (NASDAQ:MLAB) saw a significant decrease of 12.1% in January, totaling 246,660 shares, which represents about 4.7% of the company's stock. The days-to-cover ratio is currently 2.2 days based on an average daily trading volume of 110,124 shares. The company also announced a quarterly dividend of $0.16 per share, and analysts currently have a consensus "Reduce" rating with an average target price of $83.00.
Mesa Laboratories Q3 Earnings Summary & Key Takeaways
Mesa Laboratories (NASDAQ: MLAB) announced its Q3 earnings on February 3, 2026, reporting an EPS of $3.07, significantly beating the estimated $1.6. This represents a 92.0% beat on earnings, with revenue also showing a $2.29 million increase year-over-year. The company's previous quarter also saw an EPS beat, leading to a share price increase.
Mesa Labs stock soars to 52-week high of $149.5 amid robust growth
Mesa Labs (MLAB) stock surged to a 52-week high of $149.5, indicating robust growth. This significant price movement suggests strong investor confidence and positive market sentiment for the company.
Mesa Laboratories (NASDAQ:MLAB) Has Affirmed Its Dividend Of $0.16
Mesa Laboratories (NASDAQ:MLAB) has affirmed a dividend of $0.16, yielding 0.8%, which is above the industry average. Despite not being profitable, the company's dividend is projected to be sustainable due to strong free cash flow and expected EPS growth in the coming year, although its long-term dividend growth potential is considered shaky due to past EPS declines. The article advises caution for income-focused investors due to concerns about the dividend's long-term sustainability despite consistent payments.
Mesa Laboratories (NASDAQ:MLAB) Has Affirmed Its Dividend Of $0.16
Mesa Laboratories (MLAB) has declared a dividend of $0.16, payable on March 16th, resulting in a 0.8% yield. While the company is not profitable, its dividend appears sustainable as it pays out less than 75% of its free cash flow. Despite a historical decline in EPS, forecasts suggest a 60.1% rise next year, offering some comfort regarding future dividend payments.
Mesa Laboratories' (NASDAQ:MLAB) Dividend Will Be $0.16
Mesa Laboratories (NASDAQ:MLAB) has announced a dividend of $0.16 per share payable on March 16th, representing an annual yield of 0.8%. While the company is not currently profitable, its dividend is covered by free cash flow. Analysts expect EPS to grow by 60.1% over the next year, but the company's dividend growth potential is considered limited due to past earnings per share declines.
Mesa Laboratories (NASDAQ:MLAB) Has Affirmed Its Dividend Of $0.16
Mesa Laboratories (NASDAQ:MLAB) has announced a dividend of $0.16 per share, to be paid on March 16th, resulting in a 0.8% yield. While the company is not currently profitable, it pays out less than 75% of its free cash flow, suggesting the dividend may be sustainable despite past EPS declines. However, analysts express concern about the long-term sustainability due to a lack of consistent EPS growth.
MESA LABS DECLARES QUARTERLY DIVIDEND
Mesa Laboratories, Inc. (NASDAQ:MLAB) announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend is payable on March 16, 2026, to shareholders of record as of February 28, 2026. Mesa is a global leader in life science tools and quality control solutions for regulated industries.
MESA LABS DECLARES QUARTERLY DIVIDEND
Mesa Laboratories, Inc. (NASDAQ:MLAB) announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on March 16, 2026, to shareholders of record at the close of business on February 28, 2026. Mesa is a global leader in life science tools and critical quality control solutions.
MESA LABS DECLARES QUARTERLY DIVIDEND
Mesa Laboratories, Inc. (NASDAQ:MLAB) announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on March 16, 2026, to shareholders of record as of February 28, 2026. Mesa is a global leader in life science tools and quality control solutions for regulated industries.
Insiders Who Sold Mesa Laboratories Missed Out On 11% Stock Increase
Insiders who sold Mesa Laboratories (MLAB) stock over the last year, specifically VP & CFO John Sakys, at an average price of US$97.12, likely made a good decision as the stock is now valued lower at US$87.25, despite an 11% increase last week. Despite the sale, insiders still own 3.1% of the company, valued at US$15m, indicating some alignment with shareholders. The article suggests that while insider selling is not always negative, the sale at a higher price was advantageous for the insider.
Insiders Who Sold Mesa Laboratories Missed Out On 11% Stock Increase
Mesa Laboratories (NASDAQ:MLAB) stock recently rose 11%, but insiders who sold US$62k worth of stock last year at an average price of US$97.12 are likely in a better position, as this selling price was higher than the current US$87.25. The company's VP, CFO & Chief Accounting Officer, John Sakys, was the sole insider seller. While insiders own 3.1% of Mesa Laboratories shares, aligning their interests with shareholders, the recent lack of insider trading activity suggests a neutral outlook.
Mesa Labs to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
Mesa Laboratories, Inc. (NASDAQ:MLAB) announced that its President and CEO, Gary Owens, and CFO, John Sakys, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The presentation is scheduled for 4:30 p.m. Pacific Time and a live webcast will be available via the company's investor relations website, with an archived replay accessible afterward. Mesa Labs specializes in life science tools and critical quality control solutions for regulated industries.
Mesa Labs to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
Mesa Laboratories, Inc. (NASDAQ: MLAB) announced that its President and CEO, Gary Owens, and CFO, John Sakys, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The presentation will occur at 4:30 p.m. Pacific Time and a live webcast will be available on Mesa Lab's Investor Relations website. An archived replay will also be accessible following the event.
Mesa Labs to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
Mesa Laboratories, Inc. announced that its President and CEO, Gary Owens, and CFO, John Sakys, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 4:30 p.m. Pacific Time. A live webcast of their presentation will be available on Mesa Lab’s Investor Relations website, with an archived replay accessible afterward. Mesa Labs is a global leader in life science tools and quality control solutions for the pharmaceutical, healthcare, and medical device industries.
Mesa Laboratories (NASDAQ:MLAB) Price Target Raised to $83.00
Wells Fargo & Company increased its price target for Mesa Laboratories (NASDAQ:MLAB) from $75.00 to $83.00, maintaining an "equal weight" rating, suggesting a potential 6.12% upside. Despite this, the consensus among analysts remains a "Sell," with one Hold and two Sell ratings. Institutional investors have actively traded MLAB shares, with hedge funds and other institutions owning 90.60% of the stock.
Wells Fargo Maintains Mesa Laboratories (MLAB) Equal-Weight Recommendation
Wells Fargo has maintained its "Equal-Weight" recommendation for Mesa Laboratories (MLAB). The average one-year price target for MLAB is $96.90/share, suggesting a potential upside of 24.60% from its last closing price. Institutional ownership in Mesa Laboratories has seen a slight decrease, though major holders like Conestoga Capital Advisors maintain significant positions.
Mesa Laboratories (NASDAQ:MLAB) Stock Rating Upgraded by Zacks Research
Zacks Research upgraded Mesa Laboratories (NASDAQ:MLAB) to a "strong sell" rating. MarketBeat indicates a consensus "Sell" rating with a target price of $67.00, while the stock recently traded at $77.77, above this target. Institutional investors hold a significant portion of MLAB shares, with several hedge funds increasing or initiating positions in Q3.
Mesa Laboratories, Inc. $MLAB Shares Sold by Ranger Investment Management L.P.
Ranger Investment Management L.P. decreased its stake in Mesa Laboratories (NASDAQ:MLAB) by 7.2% in Q2, selling 16,698 shares and ending the quarter with holdings valued at $20.19 million. Institutional investors now own 90.60% of the company, which has a market cap of $429.3 million and a dividend yield of 0.8%. Analysts currently have a consensus "Sell" rating for MLAB with a target price of $67.00.
Biological & Chemical Indicators Market Set to Witness Robust Growth Through 2035
The Biological & Chemical Indicators Market is projected to grow from USD 549.8 million in 2025 to USD 904.2 million by 2035, driven by increasing infection control demand and stringent regulations. North America leads the market, with significant growth also expected in Europe and APAC due to advancements in sterilization monitoring and healthcare infrastructure. Key players are focusing on digital integration and rapid-readout technologies to meet evolving market demands.
Kennedy Capital Management LLC Cuts Stake in Mesa Laboratories, Inc. $MLAB
Kennedy Capital Management LLC reduced its stake in Mesa Laboratories, Inc. by 20.1% in Q2 2025, selling 22,792 shares but still retaining a significant holding valued at approximately $8.53 million. Institutional ownership of Mesa Laboratories stands around 90.6%. Analyst sentiment for MLAB is mixed-to-negative, with an average target price of $67.00.
Mesa Laboratories, Inc. to Announce Third Quarter Results on February 3, 2026
Mesa Laboratories, Inc. (NASDAQ:MLAB) will release its third-quarter financial results for fiscal year 2026 on Tuesday, February 3, 2026, at approximately 8:00 A.M. Eastern Time. The company, a global leader in life science tools and quality control solutions, aims to ensure product integrity and improve patient safety.
Mesa Laboratories, Inc. to Announce Third Quarter Results on February 3, 2026
Mesa Laboratories, Inc. (NASDAQ:MLAB) announced that it will release its financial results for the third quarter of fiscal year 2026 on Tuesday, February 3, 2026, at approximately 8:00 A.M. Eastern Time. The company, a global leader in life science tools and quality control solutions, provides products and services for regulated applications in the pharmaceutical, healthcare, and medical device industries.
Mesa Laboratories, Inc. to Release Third Quarter Financial Results for Fiscal Year 2026 on February 3, 2026
Mesa Laboratories, Inc. announced it will release its Q3 fiscal year 2026 financial results on February 3, 2026, at 8:00 A.M. ET. The company is a leader in life science tools and quality control solutions for the pharmaceutical, healthcare, and medical device industries. Despite recent insider selling, the upcoming earnings release and the company's focus on product integrity and patient safety are highlighted as potential positives for investor confidence.
Here's Why Mesa Laboratories (NASDAQ:MLAB) Can Manage Its Debt Responsibly
Mesa Laboratories (NASDAQ:MLAB) has US$152.9m in net debt, a reduction from the prior year, and its ability to convert EBIT to free cash flow suggests it can manage this debt. However, a low interest cover ratio of 1.4 times indicates high leverage due to significant depreciation and amortization, prompting cautionary observation despite recent EBIT growth. The company's market capitalization of US$429.3m provides a potential avenue for raising cash if needed.
Here's Why Mesa Laboratories (NASDAQ:MLAB) Can Manage Its Debt Responsibly
Mesa Laboratories (NASDAQ:MLAB) has reduced its debt, showing US$152.9m in net debt as of September 2025. While the company's net debt to EBITDA ratio is 3.8, its low interest cover of 1.4 times raises some caution due to significant depreciation and amortization charges. However, Mesa Laboratories' strong free cash flow generation, which exceeds its EBIT, suggests it should be able to manage its debt obligations effectively.
Diamond Hill Capital Small Cap Strategy’s Views on Mesa Laboratories (MLAB)
Diamond Hill Capital's Small Cap Strategy shared its views on Mesa Laboratories, Inc. (MLAB) in its Q3 2025 investor letter. Despite being a "bottom contributor" with modest growth affected by macroeconomic factors, Mesa Laboratories' largest segment showed solid core growth. The fund noted that MLAB is not among the 30 most popular stocks among hedge funds, and while it poses risks and potential, they believe certain AI stocks offer greater short-term upside.
Mesa Laboratories (NASDAQ: MLAB) to join Jefferies chat; live webcast Nov 20, 12:00 GMT
Mesa Laboratories (NASDAQ:MLAB) announced that its senior management, Gary Owens (President and CEO) and John Sakys (CFO), will participate in three investor conferences in November and December 2025. They will hold 1x1 meetings at the Raymond James Napa Valley Small Cap Symposium, conduct a fireside chat at the Jefferies London Healthcare Conference which will be live-webcast, and also participate in a fireside chat at the 8th Annual Evercore Healthcare Conference. The Jefferies fireside chat is scheduled for November 20, 2025, at 12:00 p.m. GMT, with a replay available on Mesa Lab's Investor Relations website.
MESA LABORATORIES INC /CO/ SEC 10-Q Report
Mesa Laboratories Inc. (MLAB) has released its Form 10-Q report for Q3 fiscal year 2025, detailing financial performance including a 5% revenue increase to $60.7 million and a 34.7% rise in operating income, despite a 27.8% decrease in net income. The report highlights varied segment performances with growth in Biopharmaceutical Development and Calibration Solutions, but declines in Clinical Genomics due to challenges in China, where the company faces macroeconomic and regulatory headwinds. Mesa Labs is implementing cost-saving initiatives and reinvesting in other divisions to mitigate these challenges.
Mesa Laboratories Inc reports results for the quarter ended September 30 - Earnings Summary
Mesa Laboratories Inc (MLAB) reported adjusted earnings of 45 cents per share for the quarter ended September 30, surpassing analysts' average expectation of 16 cents. Revenue increased by 5% to $60.74 million, aligning with estimates. Despite a quarterly rise in share price, the company's stock has seen a significant decline year-to-date.
Mesa Laboratories Inc reports results for the quarter ended June 30 - Earnings Summary
Mesa Laboratories Inc reported adjusted earnings of 85 cents per share for the quarter ended June 30, significantly beating analyst expectations of 44 cents per share. Revenue increased by 2.4% to $59.54 million, though it fell short of analyst estimates. The company's shares have experienced a significant decline this quarter and year-to-date, with analysts maintaining a "hold" rating with a median price target of $120.00.
Trading Systems Reacting to (MLAB) Volatility - news.stocktradersdaily.com
Stock Traders Daily reports on Mesa Laboratories Inc. (NASDAQ: MLAB) volatility, highlighting strong near- and mid-term sentiment but a weak long-term outlook. The analysis provides AI-generated trading strategies for different risk profiles, including long, breakout, and short positions, alongside multi-timeframe signal analysis and support/resistance levels. The article emphasizes a significant risk-reward setup targeting a 27.9% gain versus 0.3% risk.
$0.16 per share: Mesa Labs Declares Quarterly Dividend Payable Dec 15; Record Date Nov 28
Mesa Laboratories (NASDAQ:MLAB) announced on October 3, 2025, that its Board of Directors declared a regular quarterly dividend of $0.16 per share of common stock. This dividend is scheduled to be payable on December 15, 2025, to shareholders who are on record as of the close of business on November 28, 2025. The news prompted a moderate positive market reaction, with MLAB stock gaining 2.85% on the day of the announcement.
Mesa Labs Shares Surge Following Key Strategic Develops
Mesa Laboratories Inc. (MLAB) shares surged by 5.74% due to strategic developments and promising advancements in lab technologies. The company's stock shows potential for continued upward movement in the short term, despite underlying profitability and debt challenges. Analyst sentiment remains neutral, acknowledging growth potential balanced by financial constraints.
